Piper Sandler Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $43
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro has initiated coverage on Revolution Medicines (NASDAQ:RVMD) with an Overweight rating and set a price target of $43.
March 11, 2024 | 10:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler initiated coverage on Revolution Medicines with an Overweight rating and a price target of $43.
The initiation of coverage by Piper Sandler with an Overweight rating and a price target of $43 is a positive signal for investors, indicating a bullish outlook on Revolution Medicines. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100